SC
SPRB

Stempoint Capital’s Spruce Biosciences SPRB Stock Holding History

Stempoint Capital’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.23M Buy
41,388
+35,028
+551% +$1.96M 0.39% 61
2026
Q1 		$416K Buy
+6,360
New +$439K 0.08% 71

Other funds holding SPRB

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Stempoint Capital's SPRB Position: Q2 2026 in Review

Stempoint Capital increased its Spruce Biosciences (SPRB) stake by 551% in Q2 2026, buying an estimated $1.96M and bringing the position to 41,388 shares worth $2.23M. The position accounts for 0.39% of the portfolio, ranked #61.

Stempoint Capital first reported a position in SPRB in Q1 2026 and has held it in 2 quarters since. 57 funds tracked by Wall St. Rank hold SPRB as of Q2 2026.

  • Stempoint Capital held 41,388 shares of Spruce Biosciences worth $2.23M as of Q2 2026.
  • Stempoint Capital bought 35,028 Spruce Biosciences shares in Q2 2026, an estimated $1.96M.
  • Spruce Biosciences made up 0.39% of Stempoint Capital's portfolio in Q2 2026, its #61 holding.
  • Stempoint Capital first reported a position in Spruce Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 57 funds tracked by Wall St. Rank held Spruce Biosciences as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.